Syndax grants CFO Aaron Ondrey options to buy up to 270,000 shares
SNDX•Syndax Pharmaceuticals granted incoming CFO Aaron A. Ondrey an option to buy up to 270,000 common shares at $9.55 per share. The award vests over four years, beginning with 25% on the first anniversary of the vesting commencement date.
1. Option award terms
Syndax Pharmaceuticals granted incoming Chief Financial Officer Aaron A. Ondrey a stock option to purchase up to 270,000 common shares. His appointment took effect November 9, 2026, and the option has an exercise price of $9.55 per share.
2. Vesting schedule
Twenty-five percent of the award vests on the first anniversary of the vesting commencement date. The remaining shares vest in monthly installments of 1/48th over 36 months, subject to Ondrey’s continued service through the applicable vesting dates.
